Endothelin antagonist as add-on treatment for proteinuria in diabetic nephropathy: is there light at the end of the tunnel?

J Am Soc Nephrol. 2011 Apr;22(4):593-5. doi: 10.1681/ASN.2011020158. Epub 2011 Mar 17.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Albuminuria / drug therapy
  • Albuminuria / etiology
  • Atrasentan
  • Diabetic Nephropathies / complications*
  • Endothelins / antagonists & inhibitors*
  • Glomerular Filtration Rate / drug effects
  • Glomerular Filtration Rate / physiology
  • Humans
  • Proteinuria / drug therapy*
  • Proteinuria / etiology*
  • Proteinuria / physiopathology
  • Pyridines / adverse effects
  • Pyridines / pharmacology
  • Pyridines / therapeutic use
  • Pyrimidines / adverse effects
  • Pyrimidines / pharmacology
  • Pyrimidines / therapeutic use
  • Pyrrolidines / adverse effects
  • Pyrrolidines / pharmacology
  • Pyrrolidines / therapeutic use
  • Renin-Angiotensin System / drug effects
  • Renin-Angiotensin System / physiology
  • Treatment Outcome

Substances

  • Endothelins
  • Pyridines
  • Pyrimidines
  • Pyrrolidines
  • Avosentan
  • Atrasentan